Literature DB >> 33477693

Expanding the Scope of the Cleavable N-(methoxy)oxazolidine Linker for the Synthesis of Oligonucleotide Conjugates.

Aapo Aho1, Antti Äärelä1, Heidi Korhonen1, Pasi Virta1.   

Abstract

Oligonucleotides modified by a 2'-deoxy-2'-(N-methoxyamino) ribonucleotide react readily with aldehydes in slightly acidic conditions to yield the corresponding N-(methoxy)oxazolidine-linked oligonucleotide-conjugates. The reaction is reversible and dynamic in slightly acidic conditions, while the products are virtually stable above pH 7, where the reaction is in a ''switched off-state''. Small molecular examinations have demonstrated that aldehyde constituents affect the cleavage rate of the N-(methoxy)oxazolidine-linkage. This can be utilized to adjust the stability of this pH-responsive cleavable linker for drug delivery applications. In the present study, Fmoc-β-Ala-H was immobilized to a serine-modified ChemMatrix resin and used for the automated assembly of two peptidealdehydes and one aldehyde-modified peptide nucleic acid (PNA). In addition, a triantennary N-acetyl-d-galactosamine-cluster with a β-Ala-H unit has been synthesized. These aldehydes were conjugated via N-(methoxy)oxazolidine-linkage to therapeutically relevant oligonucleotide phosphorothioates and one DNA-aptamer in 19-47% isolated yields. The cleavage rates of the conjugates were studied in slightly acidic conditions. In addition to the diverse set of conjugates synthesized, these experiments and a comparison to published data demonstrate that the simple conversion of Gly-H to β-Ala-H residue resulted in a faster cleavage of the N-(methoxy)oxazolidine-linker at pH 5, being comparable (T0.5 ca 7 h) to hydrazone-based structures.

Entities:  

Keywords:  N-(methoxy)oxazolidine; cleavable linker; oligonucleotide conjugates

Year:  2021        PMID: 33477693      PMCID: PMC7838870          DOI: 10.3390/molecules26020490

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  54 in total

1.  Receptor mediated uptake of peptides that bind the human transferrin receptor.

Authors:  J H Lee; J A Engler; J F Collawn; B A Moore
Journal:  Eur J Biochem       Date:  2001-04

2.  Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.

Authors:  Xing Xian Yu; Susan F Murray; Sanjay K Pandey; Sheri L Booten; Dingjiu Bao; Xiu-Zhen Song; Susan Kelly; Songyuan Chen; Robert McKay; Brett P Monia; Sanjay Bhanot
Journal:  Hepatology       Date:  2005-08       Impact factor: 17.425

3.  Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras.

Authors:  James O McNamara; Eran R Andrechek; Yong Wang; Kristi D Viles; Rachel E Rempel; Eli Gilboa; Bruce A Sullenger; Paloma H Giangrande
Journal:  Nat Biotechnol       Date:  2006-06-25       Impact factor: 54.908

4.  Synthesis of oligonucleotide glycoconjugates using sequential click and oximation ligations.

Authors:  Marika Karskela; Mia Helkearo; Pasi Virta; Harri Lönnberg
Journal:  Bioconjug Chem       Date:  2010-04-21       Impact factor: 4.774

Review 5.  Oligonucleotide-Based Therapeutics: An Emerging Strategy for the Treatment of Chronic Liver Diseases.

Authors:  Naim Alkhouri; G Kesava Reddy; Eric Lawitz
Journal:  Hepatology       Date:  2021-03-16       Impact factor: 17.425

Review 6.  Antisense oligonucleotides: the next frontier for treatment of neurological disorders.

Authors:  Carlo Rinaldi; Matthew J A Wood
Journal:  Nat Rev Neurol       Date:  2017-12-01       Impact factor: 42.937

7.  Suppression of diacylglycerol acyltransferase-2 (DGAT2), but not DGAT1, with antisense oligonucleotides reverses diet-induced hepatic steatosis and insulin resistance.

Authors:  Cheol Soo Choi; David B Savage; Ameya Kulkarni; Xing Xian Yu; Zhen-Xiang Liu; Katsutaro Morino; Sheene Kim; Alberto Distefano; Varman T Samuel; Susanne Neschen; Dongyan Zhang; Amy Wang; Xian-Man Zhang; Mario Kahn; Gary W Cline; Sanjay K Pandey; John G Geisler; Sanjay Bhanot; Brett P Monia; Gerald I Shulman
Journal:  J Biol Chem       Date:  2007-05-27       Impact factor: 5.157

8.  Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies.

Authors:  John F DiJoseph; Douglas C Armellino; Erwin R Boghaert; Kiran Khandke; Maureen M Dougher; Latha Sridharan; Arthur Kunz; Philip R Hamann; Boris Gorovits; Chandrasekhar Udata; Justin K Moran; Andrew G Popplewell; Sue Stephens; Philip Frost; Nitin K Damle
Journal:  Blood       Date:  2003-11-13       Impact factor: 22.113

9.  Cholesterol-Containing Nuclease-Resistant siRNA Accumulates in Tumors in a Carrier-free Mode and Silences MDR1 Gene.

Authors:  Ivan V Chernikov; Daniil V Gladkikh; Mariya I Meschaninova; Alya G Ven'yaminova; Marina A Zenkova; Valentin V Vlassov; Elena L Chernolovskaya
Journal:  Mol Ther Nucleic Acids       Date:  2017-01-03

Review 10.  Oligonucleotide Therapeutics as a New Class of Drugs for Malignant Brain Tumors: Targeting mRNAs, Regulatory RNAs, Mutations, Combinations, and Beyond.

Authors:  Anna M Krichevsky; Erik J Uhlmann
Journal:  Neurotherapeutics       Date:  2019-04       Impact factor: 7.620

View more
  1 in total

1.  A Versatile Solid-Phase Approach to the Synthesis of Oligonucleotide Conjugates with Biodegradable Hydrazone Linker.

Authors:  Mariya I Meschaninova; Nina S Entelis; Elena L Chernolovskaya; Alya G Venyaminova
Journal:  Molecules       Date:  2021-04-07       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.